Issued on behalf of Premaitha Health plc
Manchester, UK: Tuesday, 26 January 2016
Update on UK Litigation Timing
Manchester, UK – 26 January 2016: Premaitha Health PLC (“Premaitha” or “the Company”; AIM: NIPT) provides investors with visibility of the timelines involved in the UK litigation previously lodged by Illumina.
The Company has been advised that a date has now been set for the High Court to hear the first claim lodged by Illumina in March 2015. These proceedings will take place in early October 2016 and the outcome is likely to be known by Christmas 2016, subject to any appeals.
No date has currently been set for the proceedings of the second claim lodged by Illumina in October 2015. The Company understands these will not be before 1 January 2017.
Dr Stephen Little, CEO, Premaitha commented: “We fully understand that investors are keen for clarification on how the legal process in the UK will unfold. Therefore, as we have done today, we will continue to update investors as and when possible even though the process is inherently complex, timelines uncertain and much detailed information must by necessity remain confidential.
“We continue to defend these actions robustly and we remain focused on delivering patient choice through high quality non-invasive prenatal testing in the UK and internationally.”
– Ends –
For more information, please contact:
Premaitha Health PLC
Dr Stephen Little, Chief Executive Officer
Jo Cross, Head of Marketing
Tel: +44 (0) 161 667 6865
Email: investors@premaitha.com
Email: joanne.cross@premaitha.com
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Avi Robinson
Tel: +44 (0) 20 7148 7900
Panmure Gordon (UK) Limited (Broker)
Robert Naylor / Freddy Crossley / Maisie Rose Atkinson
Tel: +44 (0) 20 7886 2500
Instinctif Partners (Media)
Melanie Toyne Sewell / Jayne Crook / Jen Lewis
Tel: +44 (0) 207 457 2020
Email: premaitha@instinctif.com
About Premaitha Health
Premaitha is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha’s flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer CE-marked NIPT in-house for the first time.
The IONA® test estimates the risk of a fetus having Down’s syndrome. The IONA® test has a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors greater confidence in the result and reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their own facilities. This supports Premaitha’s strategy of accelerating the broad dissemination of NIPT tests to ensure that their benefits are available to pregnant women everywhere.
Premaitha is listed on the London Stock Exchange (AIM). Its R&D, manufacturing and commercial operation is located at Manchester Science Park, UK. For further information please visit www.premaitha.com or email iona@premaitha.com
